Ivermectin

Ivermectin is a macrocyclic lactone antiparasitic agent that has revolutionized the treatment and prevention of parasitic diseases in both human and veterinary medicine since its introduction in the 1980s. In canine medicine, ivermectin is widely used for the treatment of various mite infestations, including sarcoptic mange, demodectic mange, ear mites, and cheyletiellosis. While ivermectin is FDA-approved for heartworm prevention in dogs at low doses, its use for mite treatment typically involves higher doses and constitutes off-label use, requiring careful veterinary supervision and patient selection.

The mechanism of action of ivermectin involves potentiation of glutamate-gated chloride channels in invertebrate nerve and muscle cells. When ivermectin binds to these channels, it causes an influx of chloride ions that hyperpolarizes the cell membranes, resulting in paralysis and death of the parasite. Mammals possess glutamate-gated chloride channels in the central nervous system, but these are normally protected from ivermectin exposure by the blood-brain barrier. This selectivity accounts for the drug's generally favorable safety profile in most dogs, though genetic variations affecting the blood-brain barrier can dramatically increase sensitivity to ivermectin's neurotoxic effects.

Ivermectin is available in multiple formulations for veterinary use, including oral solutions, injectable preparations, and topical products. For mite treatment in dogs, the oral route is most commonly employed, often using diluted large animal formulations administered daily or every other day. The specific formulation, dosage, and treatment duration depend on the type of mite being treated and the individual patient's response to therapy. Injectable ivermectin may be used in some protocols, particularly for initial treatment or in patients that cannot receive oral medications.

The safety of ivermectin in dogs varies dramatically depending on genetic factors, particularly the presence of the MDR1 gene mutation that affects P-glycoprotein function at the blood-brain barrier. Dogs with this mutation can experience severe, potentially fatal neurotoxicity at doses that would be safe in unaffected dogs. This genetic sensitivity makes proper patient screening, breed awareness, and careful dose selection absolutely essential when using ivermectin for mite treatment. The discovery of the MDR1 mutation has fundamentally changed how veterinarians approach ivermectin therapy in susceptible breeds.

Sarcoptic mange, caused by the mite Sarcoptes scabiei var. canis, is one of the primary conditions treated with ivermectin in dogs. This highly contagious skin disease causes intense itching, hair loss, crusty skin lesions, and significant discomfort. Sarcoptic mange can be transmitted between dogs and temporarily to humans, making effective treatment essential both for the affected dog and for household members. Ivermectin has proven highly effective against sarcoptic mites, with resolution of clinical signs typically occurring within four to six weeks of appropriate treatment.

Demodectic mange, caused by Demodex canis mites, represents another important indication for ivermectin therapy. While localized demodicosis may resolve spontaneously, generalized demodicosis requires aggressive treatment. Ivermectin administered orally at elevated doses has been used successfully for demodicosis treatment for many years, though the prolonged treatment courses required (often three to six months or longer) and the need for careful dose escalation require dedicated owner commitment and close veterinary monitoring. The availability of isoxazoline-class oral medications has provided convenient alternatives, but ivermectin remains a viable option, particularly when cost is a significant consideration.

Ear mites (Otodectes cynotis) are another mite species that responds well to ivermectin treatment. While topical ear medications are commonly used for ear mite infestations, systemic ivermectin can be effective and may be preferred when mites have spread beyond the ear canal or when topical treatment is impractical. Systemic treatment also addresses any mites present on the body surface that might reinfest the ears. Treatment duration for ear mites is typically shorter than for sarcoptic or demodectic mange.

Cheyletiellosis, caused by Cheyletiella mites, is an additional condition where ivermectin demonstrates efficacy. These surface-dwelling mites cause a distinctive scaling dermatitis sometimes called "walking dandruff" due to the visible movement of mites among the scales. Cheyletiellosis is contagious between animals and can cause temporary skin irritation in humans. Ivermectin treatment is effective and may be preferred when multiple animals in a household are affected, as systemic treatment ensures all animals receive consistent dosing.

Beyond mite treatment, ivermectin has numerous other applications in canine medicine. At lower doses, it serves as a highly effective heartworm preventive and is a component of several commercial heartworm prevention products. It is also used for the treatment of certain intestinal parasites and may be employed in the treatment of specific eye and skin conditions. However, when discussing ivermectin for mite treatment specifically, the dosages used are substantially higher than those for heartworm prevention, which significantly affects the risk-benefit considerations for individual patients.

Dosing of ivermectin for mite treatment in dogs must be carefully individualized based on the type of mite being treated, the severity of infestation, and crucially, the individual dog's genetic sensitivity status. Unlike the fixed low doses used for heartworm prevention (typically 6 to 12 micrograms per kilogram monthly), mite treatment protocols often require daily or every-other-day dosing at significantly higher levels. The veterinarian determines the appropriate protocol after evaluating the patient's breed, health status, and MDR1 mutation risk.

For sarcoptic mange, typical treatment protocols involve ivermectin at doses of 200 to 400 micrograms per kilogram administered orally or by subcutaneous injection. Treatment is usually given every one to two weeks for a total of two to four treatments, depending on clinical response. Some protocols use lower doses given more frequently. The intense itching of sarcoptic mange typically improves within one to two weeks of initiating treatment, though complete resolution may take longer.

Demodicosis treatment requires a more intensive and prolonged protocol. After initial veterinary assessment and any necessary screening for MDR1 status, treatment typically begins with a low dose that is gradually escalated over one to two weeks until the target dose is reached. The target dose for demodicosis is typically 300 to 600 micrograms per kilogram given orally once daily, though individual protocols vary. This gradual dose escalation helps identify dogs with unexpected sensitivity before toxic doses are reached. Treatment continues daily until skin scrapings are negative for mites for at least two consecutive examinations, typically requiring three to six months or longer.

Regardless of the condition being treated, the first doses of ivermectin should be administered under conditions allowing observation for adverse effects. Some veterinarians administer the first dose in the clinic and observe the patient for several hours. Pet owners should be educated about the signs of ivermectin toxicity, including dilated pupils, disorientation, tremors, drooling, blindness, and ataxia, and instructed to discontinue treatment and seek immediate veterinary care if any of these signs occur.

Formulation selection depends on the specific product available and the treatment protocol. Oral administration using diluted large animal formulations is common, though precise measuring and dilution are critical for accurate dosing. Commercial oral solutions formulated for dogs are preferred when available, as they reduce the risk of dosing errors. Injectable formulations may be used, particularly for dogs that cannot receive oral medication or when more certain dosing is needed. Topical ivermectin products are also available and may be used in some protocols.

Owner compliance with the treatment protocol is essential for successful mite treatment. For daily dosing protocols used in demodicosis, pet owners must be committed to consistent daily administration over many months. Missed doses can allow mite populations to rebound, prolonging treatment and potentially contributing to treatment failure. Regular veterinary rechecks with skin scrapings are necessary to monitor response and determine when treatment can safely be discontinued.

Ivermectin is generally well-tolerated by most dogs when used at appropriate doses in patients without genetic sensitivity. Dogs that do not carry the MDR1 mutation and that are appropriately dosed typically experience few if any adverse effects during mite treatment. However, all dogs should be monitored during ivermectin therapy, and pet owners should be educated about potential signs of toxicity that require immediate veterinary attention.

Mild gastrointestinal effects are among the most commonly reported side effects in dogs receiving ivermectin for mite treatment. These may include decreased appetite, nausea, vomiting, or diarrhea. These effects are usually transient and may be minimized by administering the medication with food. Persistent or severe gastrointestinal symptoms should be reported to the veterinarian, as dose adjustment or alternative treatment may be needed.

Neurological toxicity is the most serious potential adverse effect of ivermectin and occurs primarily in dogs with the MDR1 gene mutation or in any dog receiving excessive doses. Early signs of ivermectin neurotoxicity include dilated pupils that are unresponsive to light, excessive salivation, and depression or lethargy. Progressive toxicity manifests as ataxia (uncoordinated movement), disorientation, apparent blindness, and tremors. Severe toxicity can result in coma and death. These signs typically appear within hours of dosing with a toxic amount and may last for days to weeks as the drug is slowly eliminated.

Dogs of certain breeds are at dramatically increased risk for ivermectin toxicity due to the MDR1 gene mutation. This mutation impairs the function of P-glycoprotein, a transport protein that normally prevents ivermectin from crossing the blood-brain barrier in significant amounts. Affected dogs can experience severe neurotoxicity at doses that would be safe in unaffected dogs. Breeds with high prevalence of the MDR1 mutation include Collies (approximately 70% affected), Australian Shepherds, Shetland Sheepdogs, English Shepherds, Old English Sheepdogs, and several other herding breeds. Mixed breed dogs with herding breed heritage may also carry the mutation.

Any dog showing signs of ivermectin toxicity requires immediate veterinary care. There is no specific antidote for ivermectin toxicity; treatment is supportive and may include intravenous fluids, nutritional support, and nursing care for recumbent patients. Lipid emulsion therapy has shown promise in accelerating ivermectin elimination in some cases. With appropriate supportive care, many dogs recover fully from ivermectin toxicity, though recovery may take weeks in severe cases.

The most significant contraindication for ivermectin use at mite-treatment doses is the presence of the MDR1 gene mutation. Dogs homozygous for this mutation (having two copies of the mutant gene) are at extremely high risk for neurotoxicity and should not receive ivermectin at elevated doses under any circumstances. Dogs heterozygous for the mutation (one mutant copy and one normal copy) may have increased sensitivity and should be treated with extreme caution, if at all, with alternative medications strongly preferred. Genetic testing is available and should be performed before initiating ivermectin therapy in any dog of a breed known to carry the mutation or in any mixed breed dog with possible herding breed heritage.

Puppies younger than six weeks of age should not receive ivermectin, as the blood-brain barrier may not be fully developed in very young animals, potentially increasing the risk of neurotoxicity. Even in puppies without the MDR1 mutation, the immature blood-brain barrier could theoretically allow greater drug penetration into the central nervous system. Most mite treatment protocols are initiated in dogs older than this threshold, but age should be confirmed before treatment begins.

Dogs with known neurological conditions or a history of seizures may be at increased risk for complications from ivermectin therapy and should be evaluated carefully before treatment. While ivermectin does not typically cause seizures in normal dogs, any pre-existing compromise to blood-brain barrier integrity or neurological function may alter the risk profile. Alternative treatments may be preferred in dogs with neurological comorbidities.

Sick or debilitated dogs, particularly those with significant liver or kidney dysfunction, may metabolize or eliminate ivermectin differently than healthy dogs. Reduced drug elimination could result in accumulation and increased risk of toxicity. Dogs with organ dysfunction should be treated with caution, with dose adjustments made as necessary and enhanced monitoring provided. The underlying health condition should be stabilized to the extent possible before initiating mite treatment.

Several drug interactions are important to consider when using ivermectin for mite treatment in dogs. The most significant interactions involve drugs that affect P-glycoprotein function or that compete for the same transport mechanisms at the blood-brain barrier. These interactions can increase ivermectin penetration into the central nervous system and potentiate neurotoxicity, even in dogs without the MDR1 mutation.

Ketoconazole and other azole antifungal medications inhibit P-glycoprotein and can increase ivermectin levels in the brain. Dogs requiring antifungal therapy concurrently with ivermectin treatment should be monitored closely for signs of neurotoxicity. Similar concerns apply to other P-glycoprotein inhibitors, including certain calcium channel blockers, cyclosporine, and some antidepressants. The veterinarian should review all medications before initiating ivermectin therapy.

Spinosad, the active ingredient in the flea product Comfortis and the combination product Trifexis, has been associated with increased risk of ivermectin toxicity when the two drugs are administered together. The interaction appears to involve altered P-glycoprotein function and has resulted in neurological adverse events in some dogs. Dogs receiving spinosad-containing products should not be started on ivermectin for mite treatment until an appropriate washout period has elapsed, and vice versa. Veterinarians should review flea prevention protocols when prescribing ivermectin.

Concurrent use of other macrocyclic lactone antiparasitics with ivermectin should be avoided to prevent additive toxicity. Products containing milbemycin, moxidectin, or selamectin work through similar mechanisms and can compound the effects of ivermectin. Dogs on heartworm prevention products containing these ingredients should have their prevention protocol adjusted when ivermectin mite treatment is initiated. The veterinarian will advise on appropriate management of parasite prevention during the treatment period.

The single most important precaution with ivermectin use at mite-treatment doses is screening for the MDR1 gene mutation before initiating therapy. Genetic testing is readily available through veterinary diagnostic laboratories and can definitively determine whether a dog carries the mutation. Testing is strongly recommended for all dogs of herding breeds or with herding breed heritage, but should also be considered for any dog of unknown or mixed breeding. The consequences of administering ivermectin to an affected dog can be severe, making the modest cost of testing highly worthwhile.

Even in dogs that test negative for the MDR1 mutation, a test dose protocol is recommended when initiating ivermectin therapy for mite treatment. This involves starting with a very low dose and gradually increasing over several days while monitoring for any signs of sensitivity. The test dose protocol can identify dogs with unexpected sensitivity that might occur for reasons other than the MDR1 mutation. Any adverse signs during dose escalation should prompt discontinuation and reevaluation.

Pet owners must be thoroughly educated about the signs of ivermectin toxicity before treatment begins. Written instructions listing the warning signs should be provided, including dilated pupils, excessive drooling, ataxia, disorientation, apparent blindness, tremors, and depression. Owners should understand that any of these signs require immediate discontinuation of ivermectin and emergency veterinary care. The onset of toxicity may be delayed several hours after dosing, so monitoring should continue throughout the day after each dose.

Accurate dosing is critical for ivermectin therapy and requires precise measurement. When using large animal formulations that must be diluted, the dilution must be performed correctly and the dose measured accurately. Small errors in either dilution or measurement can result in significant under- or overdosing. Commercial preparations formulated for dogs with appropriate concentrations for accurate measuring are preferred when available. The dog's weight should be accurately determined, as ivermectin dosing is weight-based.

Regular veterinary monitoring throughout the treatment period is essential. For demodicosis treatment, which may continue for months, skin scrapings should be performed at regular intervals to assess treatment response. Blood work may be recommended periodically, particularly for long-term treatment, to monitor for any systemic effects. Pet owners should maintain close communication with their veterinarian and report any concerns promptly.

Ivermectin products should be stored according to label directions to maintain potency and safety. Most oral and injectable ivermectin formulations should be stored at room temperature, away from direct sunlight and heat sources. The products should be kept in their original containers with labels intact for reference to concentration and expiration date. Storage temperature recommendations typically range from 59 to 86 degrees Fahrenheit (15 to 30 degrees Celsius), though specific requirements may vary by formulation.

Prepared dilutions of ivermectin should be labeled clearly with the concentration, preparation date, and expiration date. Diluted solutions have variable stability depending on the diluent used and storage conditions. Generally, freshly prepared dilutions should be used within a reasonable timeframe, and veterinary guidance should be followed regarding the shelf life of diluted preparations. If there is any question about the potency or stability of a prepared solution, it should be discarded and a fresh dilution prepared.

Ivermectin products must be stored out of reach of children and animals. Concentrated preparations, including large animal formulations that may be used for dilution, are potentially dangerous if ingested in significant amounts. Child-resistant packaging should be used when available. In households with multiple pets, including cats, ivermectin products should be secured to prevent accidental exposure, as cats are more sensitive to ivermectin toxicity than dogs and can be affected by relatively small amounts.

Breed considerations are of paramount importance when using ivermectin for mite treatment in dogs due to the MDR1 gene mutation prevalence in certain breeds. Collies have the highest known prevalence of the mutation, with approximately 70% of the breed affected. Australian Shepherds have an affected rate of approximately 50%. Other breeds with significant mutation prevalence include Shetland Sheepdogs, English Shepherds, German Shepherds (small percentage), Border Collies, Old English Sheepdogs, Long-haired Whippets, and Silken Windhounds. McNabs, Longhaired Whippets, and several less common breeds also carry the mutation.

Mixed breed dogs present particular challenges for MDR1 screening decisions. Any mixed breed dog with known or suspected herding breed ancestry should be tested before ivermectin administration. Even dogs without obvious herding breed characteristics may carry the mutation if there is herding breed heritage anywhere in their background. When ancestry is unknown, genetic testing provides the only reliable method of determining MDR1 status. The increasing use of DNA testing for breed identification can provide information about heritage that informs the decision to test for MDR1.

Dogs that test negative for the MDR1 mutation can generally receive ivermectin at mite-treatment doses safely, though the test dose protocol is still recommended as a precaution. Dogs that are heterozygous (carriers with one mutant allele) may have increased sensitivity and should be treated with great caution, if ivermectin is used at all. For carrier dogs and for dogs that test positive homozygous, alternative treatments such as isoxazoline-class medications are strongly recommended.

Breed registries, breed clubs, and responsible breeders increasingly recognize the importance of MDR1 testing and may provide testing information for dogs with registered pedigrees. Some breeding programs include MDR1 status in health testing protocols. Veterinarians treating purebred dogs of affected breeds can inquire about MDR1 testing status, and many owners of affected breeds are now aware of this genetic issue. This increased awareness has improved the safety of ivermectin use by allowing more informed prescribing decisions.

The isoxazoline class of oral ectoparasiticides has largely replaced ivermectin as first-line therapy for mite treatment in dogs. Products including fluralaner (Bravecto), afoxolaner (NexGard), sarolaner (Simparica), and lotilaner (Credelio) have demonstrated excellent efficacy against both sarcoptic and demodectic mites. These medications are administered orally at intervals ranging from monthly to every three months depending on the product, offer consistent dosing without the need for dilution or gradual escalation, and do not carry the same MDR1-related toxicity concerns as ivermectin. For most patients, isoxazoline products are now considered the treatment of choice for mite infestations.

Milbemycin oxime, another macrocyclic lactone, has also been used for demodicosis treatment, typically administered orally on a daily basis. Like ivermectin, milbemycin requires careful dosing and is associated with MDR1-related sensitivity concerns, though some evidence suggests slightly greater safety margins in sensitive dogs. Milbemycin-based heartworm preventives such as Interceptor and Sentinel contain lower doses of the drug and are generally well-tolerated, but mite treatment requires substantially higher doses.

Moxidectin, available in topical formulations (Advantage Multi) and injectable forms (ProHeart), represents another alternative for mite treatment. The topical formulation is approved for sarcoptic mange treatment in dogs and offers the advantage of not requiring oral administration. However, moxidectin is also a P-glycoprotein substrate and carries similar MDR1-related concerns to ivermectin, though with potentially improved safety margins. Veterinarians may consider moxidectin when ivermectin is not suitable but macrocyclic lactone therapy is preferred over other options.